27,28 The data show that although there were no clinically relevant differences in efficacy or duration of effect between the 200 U and 300 U doses of onabotulinumtoxinA, the lower dose had a better safety profile. The main finding is that the endpoints were reached in continence and urodynamic parameters, and there was no significant difference in efficacy between the 200 U and 300 U doses. The efficacy data were presented by David Ginsberg, MD; results of quality-of-life issues of this phase III study

were also presented. In an international, multicenter, double-blind, randomized, placebo-controlled, parallel-group study, two doses of botulinum toxin type A, Inhibitors,research,lifescience,medical onabotulinumtoxinA were evaluated for the treatment of urinary incontinence caused by neurogenic detrusor overactivity. The impact of onabotulinumtoxinA on health-related quality of life (HRQoL) and patient satisfaction were also evaluated in patients with urinary incontinence due to neurogenic detrusor overactivity. Patients with urinary incontinence and neurogenic detrusor overactivity Inhibitors,research,lifescience,medical resulting from multiple sclerosis or spinal cord injury not adequately managed with anticholinergics and with 14 or more weekly incontinence episodes were treated with intradetrusor onabotulinumtoxinA

Inhibitors,research,lifescience,medical (200 or 300 U) or placebo. Patients were followed for up to 64 weeks and could request retreatment once from week 12 onward. The primary endpoint was the change from baseline in weekly incontinence episodes at week 6. Secondary Inhibitors,research,lifescience,medical endpoints included changes from baseline in maximum cystometric capacity and maximum detrusor pressure during first involuntary detrusor contraction. Changes in HRQoL were recorded by the Incontinence Quality of Life questionnaire (I-QOL) and a modified Overactive Bladder Patient Satisfaction with Treatment

Questionnaire (OAB-PSTQ). Patients (416) were Inhibitors,research,lifescience,medical randomized to receive 30 intradetrusor injections (1 mL each) of onabotulinumtoxinA, 200 U or 300 U, or placebo, performed through a cystoscope and avoiding the trigone. Patients had the this website option of discontinuing anticholinergics before Metalloexopeptidase the study or remaining on therapy. For those continuing on anticholinergics, the same dose had to be maintained throughout the study. Individuals using clean intermittent catheterization at baseline were instructed to maintain their established frequency. Individuals not using self-catheterization had to be willing to initiate it if necessary. The subjects had a mean age of 46 years with 30.5 weekly urinary incontinence episodes at baseline, and were randomized to receive placebo (n = 149) or onabotulinumtoxinA, 200 U (n = 135) or 300 U (n = 132). There were no significant differences between groups in baseline characteristics or urodynamic parameters. Results showed that the median time to a request for retreatment was 92 days in the placebo group, 256 days in the 200 U group, and 254 days in the 300 U group, respectively.